FIRST was initially a spinoff from SportClinic Zurich hived off as a specialised unit for regenerative medicine and surgery, so collaboration between the two is very intense. The two organisations share in the use and optimisation of highly advanced services.
As an example, the necessary surgical procedures at SportClinic are also carried out at the Hirslanden Clinic.
We also work closely with the physiotherapy institutions at SportClinic Zurich, developing coordinated treatments for regenerative medicine and surgery within this network.
We also maintain close collaboration with the department of radiology at Sport Clinic Zurich. Our radiologists Christian Fuchs and Manfred Rütschle are highly specialised in diagnosing the whole musculoskeletal system.
Our radiologists are also highly qualified in all kinds of injection treatments, which they perform to a great level of accuracy in PRP therapy using X-rays, ultrasound, or CT.
Swisscom provides us with an easy, up-to-date and secure technology to communicate with our patients, which is increasingly becoming digitalised – whether in the admission or follow-up treatment of patients.
Among other things, we also use the evita electronic health record from Swisscom that allows a secure exchange of information and documents between patients and us. At the same time, our patients always have a clear overview of their health information and benefit from a convenient messaging system when new information is available to them.
As a project partner of Swisscom, FIRST is committed to the further development of IT solutions for medical practices and new approaches in electronic communication between physician and patient.
We place a great level of importance on providing the highest possible safety and quality in the new area of regenerative medicine. We have joined RoRegistry.org to register our data in an international database developed specifically for this kind of biological therapy. This wide pool of data can serve towards rapidly developing extensive anonymous statistics on patient safety; the registered data also contributes to developing new treatment options.
The Biotechnology Institute in Spain leads the world in regenerative medicine, and has produced over a hundred indexed publications; the institute is also one of our main partners as a supplier of the plasma rich in growth factors (PRGF Endoret) that we use in PRP therapy, and for exchanging research, development, and applications.
Endoret has already been used in 700,000 patients without a single incident reported. All Endoret products have bacteriostatic and bactericidal properties. PRGF Endoret is the only platelet-rich plasma product with proven effectiveness in the treatment of osteoarthritis in two level 1 studies – that is, studies of the highest scientific quality.
TOBI is the leading institute in America with highly extensive experience in biological treatment applications. The institute holds the world’s largest specialised event every year, the PRP and Regenerative Medicine Symposium, with practical workshops on treatment applications as well as presentations by leading specialists.
After years of personal contact with TOBI founder Steven Sampson, we are part of a well-run network to assist in valuable discussions including difficult or unusual cases.
The International Cartilage Research Society (ICRS) is another important network where we as members have been going to conferences and keeping up to speed on the state of the art in optimising treatments for our patients. This expertise on the latest developments, especially in results from the clinical applications, has made it possible for us to apply the latest treatments with bioactive agents at the highest possible level.